View Author
patient study cancer treatment grade phase level toxicity inhibitor tumor cycle pharmacokinetic plasma activity effect agent death infusion trial response paclitaxel disease administration growth dose level concentration table intervention result phase i study dose levels oncol transferase therapy phase i sam 486 analysis tumour chemotherapy irinotecan sample farnesyl blood inhibition combination phase i studies function schedule matrix metastatic range diarrhea protein carcinoma metalloproteinase mmi 270b number event factor bevacizumab chapter target research telatinib cohort survival cisplatin pki 166 food intake metastatic colorectal cancer change carboplatin parameter oncology model kinase tosedostat esken ctcae regimen
10 Most Recent Publications
|
Increased alpha-fetoprotein serum level is predictive for survival and recurrence of hepatocellular carcinoma in non-cirrhotic livers
(Article)
Witjes, C.D.M. Polak, W.G. Verhoef, C. Eskens, F.A.L.M. Dwarkasing, R.S. Verheij, J. Man, R.A. de IJzermans, J.N.M. |
2013-04-01
|
|
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
(Article)
Steeghs, N. Gelderblom, A.J. Wessels, J. Eskens, F.A.L.M. Bont, N. de Nortier, J.W. Guchelaar, H.J. |
2011-02-01
|
|
Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma
(Article)
Doorn, L. van Eskens, F.A.L.M. Visser, T.J. Lugt, A. van der Mathijssen, R.H.J. Peeters, R.P. |
2011-02-01
|
|
A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours
(Article)
Herpen, C.M.L. Eskens, F.A.L.M. Jonge, M.J.A. de Desar, I. Hooftman, L. Bone, E. Timmerbonte, J.N.H. Verweij, J. |
2010-10-26
|
|
Phase i and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours
(Article)
Konings, I.R.H.M. Jonge, M.J.A. de Burger, H. Gaast, A. van der Beijsterveldt, L.E.C. van Winkler, H. Verweij, J. Yuan, Z. Hellemans, P. Eskens, F.A.L.M. |
2010-09-28
|
|
The addition of pravastatin to chemotherapy in advanced gastric carcinoma: A randomised phase II trial
(Article)
Konings, I.R.H.M. Gaast, A. van der Wijk, L.J. Jongh, F.E. de Eskens, F.A.L.M. Sleijfer, S. |
2010-08-19
|
|
Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
(Article)
Eskens, F.A.L.M. Steeghs, N. Rajagopalan, P. Gelderblom, A.J. Verweij, J. Bloem, J.L. Christensen, O. Doorn, L. van Ouwerkerk, J. Jonge, M.J.A. de Nortier, J.W. Kraetzschmar, J. |
2009-09-01
|
|
Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: A phase I study
(Article)
Mom, C.H. Verweij, J. Oldenhuis, C.N.A.M. Gietema, J.A. Fox, N.L. Miceli, R. Eskens, F.A.L.M. Loos, W.J. Vries, E.G.E. de Sleijfer, S. |
2009-09-01
|
|
Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours
(Article)
Kitzen, J.J.E.M. Jonge, M.J.A. de Lamers, C.H.J. Eskens, F.A.L.M. Biessen, D. van der Doorn, L. van Steeg, J. ter Brandely, M. Puozzo, C. Verweij, J. |
2009-07-01
|
|
Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors
(Article)
Baird, R.D. Kitzen, J.J.E.M. Kaye, S.B. Eskens, F.A.L.M. Workman, P. DeBono, J.S. Verweij, J. Clarke, P.A. Planting, A.S.T. Reade, S. Reid, A. Welsh, L. Lázaro, L.L. Las Heras, B. de Judson, I.R. |
2009-06-01
|
